TWS IP AI Report

📘 Table of Contents

1. Executive Summary

RPI 2829 reveals a dynamic convergence of pharmaceutical trademarks, advanced patents, and health-tech software innovation in Brazil. TWS IP AI detected strategic filings by leading supplement brands, global pharma giants (Novartis, Roche), and a growing ecosystem of AI-enabled healthcare software. Sectors are merging—IP is becoming cross-functional, spanning therapy, tech, and consumer experience.

2. Trademark Insights

• Top filers included supplement companies and cosmetic-health hybrids with 10–15 filings each.
• Classes 5 (pharma), 42 (software), and 44 (services) dominated activity.
• São Paulo, Minas Gerais, and Paraná led regional filings. Santa Catarina shows momentum.
• Emerging Trend: Financial institutions registering digital health brands.

3. Patent Intelligence

• Novartis: Oncology inhibitors (YAP/TAZ-TEAD), advanced form protection.
• Roche: Autoimmune therapy using novel pyridine-based compounds.
• Alebund (China): Metabolic & cardiac deuterated compounds.
• Ractigen: RNA therapies for Duchenne Muscular Dystrophy.

4. Software & Digital Health

• Key filings include AI-powered clinical platforms (e.g., Clínicas Integradas, VisCalc).
• Tech stacks: JavaScript, NodeJS, PostgreSQL, PHP, Delphi, Python.
• Filed by hospitals, startups, and universities. Many support SD-01 to SD-11 health domains.

5. Technology/Classification Mapping

Pharma Patent Codes: A61K (preparations), A61P (indications), C07K/C12N (biotech/genetic).

Software Tags: AI (IA-01), Medical SD categories (SD-01 to SD-11), management platforms (GI-01).

6. Strategic Insights & Forecasts

• White Space: Local patentable innovation in generics, tropical diseases, and AI diagnostics.
• Competitive Movement: Watch supplement and HMO firms moving into pharma-class filings.
• Digital Risk: Tech laggards may lose IP defensibility in telehealth and patient data workflows.
• Forecast: Explosion of cross-sector alliances: pharma + AI, clinics + fintech, insurers + health SaaS.